Home Methylation -Epigenetics LSD1

LSD1

Choose Selective LSD1 Inhibitors

LSD1 Products

  • All (8)
  • LSD1 Inhibitors (8)
  • New LSD1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0356 Pulrodemstat (CC-90011) besylate Pulrodemstat (CC-90011) besylate (LSD1-IN-7 benzenesulfonate) is a potent and orally active lysine specific demethylase-1 (LSD1) inhibitor that is found to be effective in various tumors.
S6722 Seclidemstat (SP-2577) Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 127 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.
S7237 OG-L002 OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
Sci Rep, 2021, 11(1):10285
Nat Genet, 2020, 52(10):1011-1017
Sci Rep, 2020, 10(1):377
S7574 GSK-LSD1 2HCl GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).
Cell Death Differ, 2022, 10.1038/s41418-022-00983-4
Theranostics, 2022, 12(4):1500-1517
Front Oncol, 2022, 12:875033
S7680 SP2509 SP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.
Biomedicines, 2022, 10(3)638
Invest Ophthalmol Vis Sci, 2022, 63(3):20
Cell Death Dis, 2021, 12(11):993
S7795 Iadademstat (ORY-1001) 2HCl ORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Mol Psychiatry, 2022, 10.1038/s41380-022-01508-8
Cell Rep, 2022, 39(5):110790
S7796 GSK2879552 2HCl GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.
Cancer Cell, 2022, S1535-6108(22)00312-9
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Mol Cell, 2021, S1097-2765(21)01037-6
S8438 T-3775440 HCl T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.
S0356 Pulrodemstat (CC-90011) besylate Pulrodemstat (CC-90011) besylate (LSD1-IN-7 benzenesulfonate) is a potent and orally active lysine specific demethylase-1 (LSD1) inhibitor that is found to be effective in various tumors.
S6722 Seclidemstat (SP-2577) Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 127 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.
S7237 OG-L002 OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
Sci Rep, 2021, 11(1):10285
Nat Genet, 2020, 52(10):1011-1017
Sci Rep, 2020, 10(1):377
S7574 GSK-LSD1 2HCl GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).
Cell Death Differ, 2022, 10.1038/s41418-022-00983-4
Theranostics, 2022, 12(4):1500-1517
Front Oncol, 2022, 12:875033
S7680 SP2509 SP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.
Biomedicines, 2022, 10(3)638
Invest Ophthalmol Vis Sci, 2022, 63(3):20
Cell Death Dis, 2021, 12(11):993
S7795 Iadademstat (ORY-1001) 2HCl ORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Mol Psychiatry, 2022, 10.1038/s41380-022-01508-8
Cell Rep, 2022, 39(5):110790
S7796 GSK2879552 2HCl GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.
Cancer Cell, 2022, S1535-6108(22)00312-9
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
Mol Cell, 2021, S1097-2765(21)01037-6
S8438 T-3775440 HCl T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.
Tags: LSD1 inhibitor | LSD1 modulator | LSD1 chemical